TURTLE Study

About The Study

Researchers at Brigham and Women’s Hospital are conducting a clinical research study for adults with mild, active ulcerative colitis.

The purpose of this study is to evaluate an investigational treatment approach involving oral study medication. The study is designed to better understand ulcerative colitis and collect information that may help inform future research.

Participation includes in-person study visits, health monitoring, and study-related procedures conducted by a qualified research team.

Quick Facts

Study Location

Brigham and Women’s Hospital – Chestnut Hill, Massachusetts

Study Duration

Approximately 12 weeks

Study Visits

7 in-person visits

Study Medication

Oral study medication provided during the study

Who Can Participate?

Are 18 years or older
Have a diagnosis of ulcerative colitis
Are currently experiencing mild, active symptoms
Are currently treated with mesalamine or sulfasalazine
Are not using biologics, immunosuppressants, JAK inhibitors, or steroids
Do not have certain medical conditions that would prevent participation

What to Expect

In-person study visits at the research site

Oral study medication

Collection of blood, stool, and urine samples

Symptom and medication tracking

Health monitoring by the study team

FAQ

We’ve pulled together some basics to help you

What is the purpose of this study?

This study is designed to evaluate an investigational treatment approach and better understand ulcerative colitis in adults with mild, active disease.

Where does the study take place?

All study visits take place in person at Brigham and Women’s Hospital – Chestnut Hill, Massachusetts.

How long does participation last?

Participation lasts approximately 12 weeks and includes seven in-person study visits.

How is my information handled?

All study-related information is handled confidentially in accordance with clinical research regulations.

Clinical Research Study for Adults With Ulcerative Colitis